Skip to Content


In the US, Metyrapone (metyrapone systemic) is a member of the following drug classes: adrenal corticosteroid inhibitors, in vivo diagnostic biologicals and is used to treat Diagnosis and Investigation.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Adrenocorticostatic agent

Diagnostic agent: Pituitary function

Chemical Name

1-Propanone, 2-metyl-1,2-di-3-pyridinyl-

Foreign Names

  • Metyraponum (Latin)
  • Metyrapon (German)
  • Métyrapone (French)
  • Metirapona (Spanish)

Generic Names

  • Metyrapone (OS: USAN, JAN, BAN)
  • Methopyrapone (IS)
  • Su 4885 (IS)
  • Metyrapone (PH: BP 2016, JP XVI, USP 38)

Brand Names

  • Metopiron
    Ceolia Pharma, Japan; HRA Pharma, Germany; LENIS, Slovenia; Medius, Switzerland
  • Metopirone
    Cherubino, Malta; Healthcare Logistics, New Zealand; HRA, Netherlands; HRA Pharma UK and Ireland, United Kingdom; HRA Pharma UK and Ireland, Ireland; Laboratoire HRA Pharma, Israel; Laboratoire HRA Pharma, Poland; Novartis, Hong Kong; Novartis Pharmaceuticals, Australia
  • Métopirone
    HRA Pharma France, France

International Drug Name Search


BANBritish Approved Name
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.